635318-26-2
Chemical Structure
Pomaglumetad methionil hydrochloride
Synonym(s): LY2140023 hydrochloride
- CAS No.: 635318-26-2
- Formula:C12H19ClN2O7S2
- Molecular Weight:402.87
IUPAC Name: (1R,4S,5S,6S)-4-((S)-2-amino-4-(methylthio)butanamido)-2-thiabicyclo[3.1.0]hexane-4,6-dicarboxylic acid 2,2-dioxide hydrochloride
InChIKey: KTYRTJLEXFSWRJ-LBMFEJOUSA-N
SMILES: CSCC[C@H](N)C(N[C@]([C@@]1([H])[C@](S2(=O)=O)([H])[C@@H]1C(O)=O)(C2)C(O)=O)=O.[H]Cl
Biological Activity: Pomaglumetad methionil hydrochloride (LY2140023 hydrochloride) is an orally active, methionine prodrug of the selective mGlu2/3 receptor agonist LY404039. Pomaglumetad methionil hydrochloride has the potential for schizophrenia research[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Pomaglumetad methionil hydrochloride | 98.0% | Pomaglumetad methionil hydrochloride (LY2140023 hydrochloride) is an orally active, methionine prodrug of the selective mGlu2/3 receptor agonist LY404039. Pomaglumetad methionil hydrochloride has the potential for schizophrenia research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Pomaglumetad methionil hydrochloride (Standard) | ≥98% | Pomaglumetad methionil hydrochloride (Standard) is the analytical standard of Pomaglumetad methionil hydrochloride (HY-105040C). This product is intended for research and analytical applications. Pomaglumetad methionil hydrochloride (LY2140023 hydrochloride) is an orally active, methionine prodrug of the selective mGlu2/3 receptor agonist LY404039. Pomaglumetad methionil hydrochloride has the potential for schizophrenia research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Lowe S, et al. Effects of a novel mGlu₂/₃ receptor agonist prodrug, LY2140023 monohydrate, on central monoamine turnover as determined in human and rat cerebrospinal fluid. Psychopharmacology (Berl). 2012 Feb;219(4):959-70. [Content Brief]
- [2]. Y Anne Pak, et al. In Vitro and Clinical Evaluations of the Drug-Drug Interaction Potential of a Metabotropic Glutamate 2/3 Receptor Agonist Prodrug with Intestinal Peptide Transporter 1. Drug Metab Dispos. 2017 Feb;45(2):137-144. [Content Brief]
